Boolean analysis of the transcriptomic data to identify novel biomarkers of IVIG response

Autoimmun Rev. 2021 Jul;20(7):102850. doi: 10.1016/j.autrev.2021.102850. Epub 2021 May 7.

Abstract

Intravenous immunoglobulin (IVIG) is used to treat several autoimmune and inflammatory diseases, but some patients are refractory to IVIG and require alternative treatments. Identifying a biomarker that could segregate IVIG responders from non-responders has been a subject of intense research. Unfortunately, previous transcriptomic studies aimed at addressing IVIG resistance have failed to predict a biomarker that could identify IVIG-non-responders. Therefore, we used a novel data mining technique on the publicly available transcriptomic data of Kawasaki disease (KD) patients treated with IVIG to identify potential biomarkers of IVIG response. By studying the boolean patterns hidden in the expression profiles of KD patients undergoing IVIG therapy, we have identified new metabolic pathways implicated in IVIG resistance in KD. These pathways could be used as biomarkers to segregate IVIG non-responders from responders prior to IVIG infusion. Also, boolean analysis of the transcriptomic data could be further extended to identify a universal biomarker that might predict IVIG response in other autoimmune diseases.

Keywords: Autoimmune diseases; Biomarkers; Boolean patterns; IVIG; Immune metabolism; Therapy; Transcriptome.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Humans
  • Immunoglobulins, Intravenous* / therapeutic use
  • Infant
  • Mucocutaneous Lymph Node Syndrome* / diagnosis
  • Mucocutaneous Lymph Node Syndrome* / drug therapy
  • Mucocutaneous Lymph Node Syndrome* / genetics
  • Retrospective Studies
  • Transcriptome

Substances

  • Biomarkers
  • Immunoglobulins, Intravenous